Royalty Pharma PLC at Citi Global Healthcare Conference Transcript
(audio in progress) biopharma analyst. And today, we have Royalty Pharma. We have Terry Coyne, CFO; Marshall Urist, EVP, Head of R&I, Research and Investments. I once said R&D and people got really -- [Dino] like almost fired me.
Questions & Answers
So I guess on the back of a very successful year, maybe, Terry, this is for you. You got rid of the external manager. You did a buyback. You sort of have the gradient of like, is it buybacks? Is it uses of cash?
You're obviously going to still invest in new assets, right? But help us with kind of where you are in that process? Are the price of assets change over the course of this year to where you would tilt towards maybe continued buybacks? Or just help us with kind of that thought.
Yes. So you mentioned the internalization that was a big strategic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
